Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGMCosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA 27.05.2022 / 15:15 Press Release (PDF)Dublin, Ireland – 27 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced th.
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 23 March 2022: Cosmo Pharmaceuticals N.V. reports full-year 2021 results for the year ended 31 December 2021,. | March 23, 2022
Cosmo Pharmaceuticals N.V. / Key word(s): Study results18-March-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland - 18 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announced tha.
Cosmo Pharmaceuticals N.V. / Key word(s): Preliminary Results15-Feb-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland - 15 February 2022: Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous30-Dec-2021 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LRDublin, Ireland - 30 December 2021: Cosmo Pharmaceuticals N.V. (SIX.